HashiCorp, Inc.

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Applied Biomics Launches New Antigen Affinity Purified HCP Antibody with 95% Coverage

Critical Infrastructure Technologies Provides an Update to its Executed Letter of Intent with H. Cegielski - Poznan S.A.

Vercel Appoints Mitchell Hashimoto, Co-Founder of HashiCorp and Creator of Terraform, to Board of Directors

Critical Infrastructure Technologies Executes a Letter of Intent with H. Cegielski - Poznan S.A.

IBM Shares Rise After Jefferies Upgrade to Buy on AI Momentum

Vercel Appoints Susan St. Ledger, former President of Worldwide Field Operations at HashiCorp, to Board of Directors

HashiCorp Previews the Future of Agentic Infrastructure Automation with Project infragraph

HashiCorp Expands Unified Lifecycle Management for Hybrid Cloud Operations

Veeva Commercial Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries

IBM closes $6.4B HashiCorp acquisition

IBM's $6.4B HashiCorp acquisition cleared by UK

UK competition watchdog clears IBM-HashiCorp $6.4 billion merger

HashiCorp to announce fourth quarter fiscal year 2025 financial results on March 6, 2025

New Strong Buy Stocks for January 29th

Here's Why HashiCorp, Inc. (HCP) is a Strong Momentum Stock

HashiCorp, Inc. (HCP) Hits Fresh High: Is There Still Room to Run?

Why HashiCorp, Inc. (HCP) is a Top Momentum Stock for the Long-Term